Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Tuberculosis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

NCT05526911
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876, Midazolam, Digoxin
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 2 Interventional

Interferon Gamma for Drug Resistant Tuberculosis

NCT00001407
View directory record Official record
Conditions
Pneumonia, Pulmonary Tuberculosis
Interventions
Interferon Gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 6:20 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

NCT05327803
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease
Interventions
Epetraborole, Placebo
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

NCT03722472
View directory record Official record
Conditions
Pulmonary TB
Interventions
ID93 + GLA-SE
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 22, 2026, 6:20 PM EDT
Completed No phase listed Observational

Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial Infection

NCT01150721
View directory record Official record
Conditions
Mycobacterium Infections, Non-tuberculous
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 22, 2026, 6:20 PM EDT
Completed No phase listed Observational

Behavioral Interventions for Control of TB

NCT00005739
View directory record Official record
Conditions
Lung Diseases, Tuberculosis
Interventions
Community-based directly observed therapy (DOT), Clinic directly observed therapy (DOT)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 2 Interventional

TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment

NCT00140309
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
moxifloxacin (with isoniazid, rifampin, pyrazinamide)
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Sep 22, 2026, 6:20 PM EDT
Completed No phase listed Observational

Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests

NCT02252198
View directory record Official record
Conditions
Tuberculosis
Interventions
Epistem Genedrive® and MolBio Truenat™
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 22, 2026, 6:20 PM EDT
Completed No phase listed Observational

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

NCT01587469
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Cepheid
Industry
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

NCT00694629
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
rifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg, rifapentine 20 mg/kg
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 22, 2026, 6:20 PM EDT
Terminated No phase listed Observational

Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali

NCT01381757
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Mycobacterium Tuberculous, Antitubercular Agents, Tuberculosis, Mulutidrug-Resistant, Extensively Drug-Resistant, Extensibely Drug-Resistant Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 22, 2026, 6:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Performance Evaluation of the VIDAS TB-IGRA Assay.

NCT04048018
View directory record Official record
Conditions
Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
Interventions
Blood draw and IGRA test
Diagnostic Test
Lead sponsor
BioMérieux
Industry
Eligibility
2 Years and older
Enrollment
2,401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

NCT00685360
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions
Delamanid, Optimized Background Regimen (OBR), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 3 Interventional

The Treatment of Tuberculosis in HIV-Infected Patients

NCT00001033
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin

NCT00000778
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyridoxine hydrochloride, Levofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 3 Interventional

TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis

NCT00023335
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2005 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

New Reusable Mask Design With Superior Filtration and Fit

NCT04826809
View directory record Official record
Conditions
Covid19, Tuberculosis, Respiratory Viral Infection
Interventions
N95 mask, Nordell single E-100 layer mask, Nordell double E-100 layer mask
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Mankato, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 22, 2026, 6:20 PM EDT
Recruiting Early Phase 1 Interventional

Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis

NCT07830771
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
[18F]-FAPI-74
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 22, 2026, 6:20 PM EDT
Completed No phase listed Observational

A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida

NCT02198079
View directory record Official record
Conditions
Cystic Fibrosis, Pediatrics
Interventions
Sputum
Biological
Lead sponsor
University of Miami
Other
Eligibility
Up to 18 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Not applicable Interventional

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

NCT00000796
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Cycloserine, Ethionamide, Capreomycin sulfate, Aminosalicylic acid, Streptomycin sulfate, Ethambutol hydrochloride, Amikacin sulfate, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
21
States / cities
Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 22, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123
View directory record Official record
Conditions
Tuberculosis, AIDS-related Complex
Interventions
Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 22, 2026, 6:20 PM EDT
Recruiting No phase listed Observational

18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

NCT07077213
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
18F-FAPI-74
Combination Product
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 22, 2026, 6:20 PM EDT